2 ms·
"Unprecedented" is a little bit unneeded considering this is a PD-1 immunotherapy used against a mismatch repair deficient cancer, these results are not surpris
by asdff 4y ago
"Unprecedented" is a little bit unneeded considering this is a PD-1 immunotherapy used against a mismatch repair deficient cancer, these results are not surprising. See Le et al NEJM 2015.
- dmix 4y agoReferring to https://www.nejm.org/doi/full/10.1056/NEJMoa1500596 https://www.nejm.org/doi/full/10.1056/NEJMoa1500596 ? Reading a follow up study: > Kaplan-Meier estimates of the 5-year OS [overall survial] rate were 31.9% for the pembrolizumab group and 16.3% for the chemotherapy group. Thirty-nine patients received 35 cycles (ie, approximately 2 years) of pembrolizumab, 82.1% of whom were still alive at data cutoff (approximately 5 years). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280089/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280089/ That's a pretty good improvement
- evandijk70 4y agoYou are comparing the wrong numbers, 5 year-OS vs objective response. Objective response is 46% in the study you cited (Table 2). 5 year-OS is nearly always lower. The patients in the new study were only followed for a median of 6.8 months, and unfortunately, the odds are high that not all of them will survive that long.